U.S. Health Spending Hits $5.7 Trillion as Weight-Loss Drugs Drive Premiums Higher

Your family's health insurance premium jumped again this year. So did your employer's contribution — money that might otherwise have gone to raises. The reason is now measurable: American health care spending surged 7.3 percent in 2025 to $5.7 trillion, the third consecutive year it increased faster than 7%, outpacing overall economic growth. Prescription drug spending rose 12.7% to $915 billion, fueled not by general cost inflation but by soaring hospital charges and pricey prescriptions — particularly GLP-1 weight-loss medications.

The impact is already in your household budget. Marketplace premiums jumped roughly 26% on average from 2025 to 2026, with some states seeing increases of 30% or more. The average Silver plan rose from $621 to $752 per month for a 40-year-old, a 21% increase. The average cost for a family of four on marketplace insurance is about $2,230 per month in 2026. Commercial group-market costs are expected to rise about 9% in 2027, with restated trends for 2026 at 9.0% for group plans and 8.5% for individual plans. Households financed roughly 27% of total national health spending in 2023, and that burden keeps growing as health spending outpaces GDP.

This isn't an abstract policy debate. It's money vanishing from paychecks and savings accounts right now.

The GLP-1 Explosion

GLP-1 weight-loss medications drove nearly half of the national increase in prescription drug spending in 2024 and remained the primary cost driver in 2025. From 2018 to 2023, GLP-1 spending increased more than 500%, rising from $13.7 billion to $71.7 billion. Use for obesity surged 586.7% nationally from 2019 to 2024. In 2025, GLP-1s surpassed specialty drug trends for the first time, becoming the largest contributor to traditional drug spending — a historic shift that puts every other therapeutic category in the shadow of a single drug class.

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) account for 70% of GLP-1 spending. The medications cost approximately $1,000 per patient per month, with retail prices without insurance ranging from $800 to $1,500. Nine percent of the U.S. population is projected to be using GLP-1 drugs by 2030 — and patients typically take them indefinitely, creating not a one-time expense but a permanent claim on household budgets, employer benefits, and public programs.

Who Pays: Employers, Governments, and You

Fifty-seven percent of employers cited GLP-1s as a major driver of overall health care cost increases in 2025. Covering the drugs could raise employer premiums by up to 14%. For some health plans, GLP-1s are the single largest cost driver, accounting for over $300 million — 20% of total pharmacy costs — in a single year. Employers are responding with greater cost-sharing, plan design changes, and reconsidered coverage for expensive therapies, intensifying affordability pressures for workers and families.

On the public side, federal health spending totaled approximately $2.5 trillion in 2025 across Medicare, Medicaid, health-related tax expenditures, veterans' care, and defense medical care. Even at a negotiated monthly price of about $245, expanded Medicare coverage of GLP-1 drugs could lead to nearly $74 billion in outlays over 10 years — with only $18 billion saved through reduced hospitalizations, resulting in net new spending of $48 billion. Some studies find no cost offsets even five years after GLP-1 initiation, as total non-GLP-1 spending increases due to higher outpatient care use.

By 2034, national health spending is expected to reach $9 trillion, accounting for 20.6% of GDP, up from 18.0% in 2024. Medicare spending is projected to grow fastest among major payers at 7.7% annually and will eventually bear 33% of the nation's health care bill by 2034, while the employer share shrinks to 17%. Federal health care costs are projected to reach roughly $3.1 trillion by 2036.

Who Gets Access: The Inequality Story

Access to GLP-1 medications for weight loss is highly unequal. Wealthier and better-insured patients are more likely to receive treatment, while lower-income and underinsured groups face substantial barriers. Prescribing data shows GLP-1 use concentrated in higher-income areas, with lower-income communities facing larger income burdens and more out-of-pocket payment. High prices and limited insurance coverage have created what some describe as a form of pharmacological privilege for those with disposable income or generous benefits.

Employer-sponsored plans are the most likely source of coverage, though they vary widely and often require meeting high BMI thresholds. Monthly out-of-pocket costs can reach hundreds to over $900 without coverage, creating a de facto divide in who can start and stay on these drugs. One-fifth of Zepbound prescriptions now come from cash-pay patients. Eli Lilly offers cash-pay prices ranging from $299 to $449 per month depending on dose. Novo Nordisk announced a 50% discount on Wegovy's list price to $675 per month for 2027.

Working families are subsidizing treatments for the affluent through their premiums and taxes while their own essential care becomes less affordable.

The Policy Dilemma: Who Decides What's Medically Necessary?

Traditional Medicare Part D does not cover GLP-1 drugs solely for weight loss due to federal law prohibitions; Medicare only covers them if prescribed for Type 2 diabetes or cardiovascular risk reduction. But CMS announced a new Medicare GLP-1 Bridge initiative to cap out-of-pocket costs for certain GLP-1 medications at $50 per month for eligible beneficiaries starting July 2026 through December 31, 2027.

"This move builds on the goal of democratizing access to weight-loss medication and aligns with the administration's plan to Make America Healthy Again," said Dr. Mehmet Oz, CMS Administrator.

"The model pairs breakthrough science with healthy living to cut costs and improve long-term health outcomes, including reducing risks for diabetes and cardiovascular disease," said Abe Sutton, CMS Innovation Center Director.

But the economics tell a different story. Health economists conclude that current GLP-1 prices far exceed accepted thresholds for cost-effectiveness, requiring a 30% price reduction for tirzepatide and an 80% reduction for semaglutide to meet the $100,000 per quality-adjusted life year benchmark.

Only 13 states covered GLP-1s for obesity through Medicaid as of early 2026, down from 16 in 2025; Pennsylvania eliminated coverage in January 2026. Only 26 out of 300 ACA Marketplace plans covered GLP-1s for obesity in 2026, a shrinking number compared to previous years.

Rationing by Bureaucracy

Insurers, employers, and public programs are already reacting with blunt cost-control tools that shift costs rather than solve the underlying crisis. Employers are pulling back on GLP-1 weight-loss coverage, raising BMI cutoffs from 30 to 35, limiting coverage to diabetics, or imposing stricter behavior-management requirements. Where coverage exists, it typically requires prior authorization documenting BMI over 30 (or 27 with comorbidities), previous unsuccessful lifestyle interventions, and periodic reauthorization tied to weight-loss outcomes. Some employers link coverage to obesity management programs, using targeted authorization to ensure GLP-1 use aligns with evidence-based clinical criteria consistent with FDA guidelines.

Novo Nordisk and Eli Lilly have adjusted pricing through lower cash prices for oral formulations and direct-to-patient channels, with oral starter doses around $149 per month and direct-to-consumer prices at $499 per month. But commercial health plans still expect medical cost trends near 9% in 2026–2027, a pace that could drive annual U.S. health spending to roughly $9 trillion by 2035 if not constrained.

The Defining Question

CMS actuaries noted that Americans are consuming more health care after a lag during the coronavirus pandemic, with utilization accelerating significantly in 2025. The trajectory of GLP-1 spending represents a fundamental tension in American health care: whether public and private payers will prioritize expensive new treatments driven by pharmaceutical pricing power, or find ways to ensure that essential care remains affordable and accessible regardless of income.

Either we confront pharmaceutical pricing power and the question of who benefits from limited resources, or we accept that essential care will become steadily less affordable as profit-driven priorities dominate spending. Every percentage point of premium increase represents a real decision in a real household: whether to take that job, whether to see that doctor, whether to fill that prescription.

The American health care system's central contradiction is now impossible to ignore: breakthrough treatments exist, funded collectively through premiums and taxes, but accessed individually only by those who can afford them. Someone will have to answer for what we're building.